Research

Mixed

The MicroSimulation Core Obesity Model (MS-COM) accurately predicts cardiovascular and mortality outcomes in adults with overweight or obesity, including those with normoglycemia, prediabetes, or type 2 diabetes, supporting its use for evaluating obesity management interventions.

For policymakers and health technology assessment bodies, the MS-COM model provides a reliable tool to evaluate the cost-effectiveness of obesity interventions (like semaglutide 2.4 mg) by accurately predicting long-term cardiovascular and mortality risks in overweight and obese adults, including those with diabetes.

GoodSupportsHIGH confidence
External validation of MS-COM showed good concordance with dependent and independent sources, suggesting the model accurately predicts obesity-related complications in an overweight/obese population with normoglycaemia/prediabetes and type 2 diabetes.
Christopher G. Fawsitt et al. · PharmacoEconomics · 2025

Why this rating

The validation uses a large number of endpoints (106) and demonstrates high linear correlation (R2 up to 0.99) in dependent validation, though independent validation for T2D incidence was weaker.

Source

External Validation of the MicroSimulation Core Obesity Model (MS-COM) to Predict Cardiovascular Outcomes, Mortality and Type 2 Diabetes Mellitus Incidence and Assess Cost Effectiveness

Christopher G. Fawsitt et al. · PharmacoEconomics · 2025

DOI 10.1007/s40273-025-01555-3

systematic_reviewCited 1×
Read the paper
DOI resolved against Crossref · corpus check 2026-06-10

This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →